Date: 2013-07-29
Type of information: Commercialisation agreement
Compound: ConfirmMDx™ for prostate cancer test
Company: MDX Health (Belgium) - Bostwick Laboratories (USA)
Therapeutic area: Cancer - Oncology
Type agreement: commercialisation
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or \
Disease: prostate cancer
Details: * On July 29, 2013, MDxHealth and Bostwick Laboratories have announced that they have entered into a marketing agreement to commercialize MDxHealth\'s ConfirmMDx™ for Prostate Cancer test. Bostwick Laboratories is a national, full-service laboratory specializing in anatomic and clinical pathology, with a focus on uropathology. The agreement provides MDxHealth with access to one of the largest urology networks in the United States.
Financial terms:
Latest news:
